Roche’s Tecentriq + Abraxane Receive FDA’s Accelerated Approval for mTNBC

 Roche’s Tecentriq + Abraxane Receive FDA’s Accelerated Approval for mTNBC

Roche’s Rozlytrek (entrectinib) Receives MHLW’s Approval for NTRK Fusion-Positive Advanced Recurrent Solid Tumors in Adult and Pediatric Patients in Japan

Shots:

  • The accelerated approval is based on P-III IMpassion130 study assessing Tecentriq + Abraxane vs PBO + Abraxane in 902 patients with PD-L1+ advanced or mTNBC with no prior therapy in ratio 1:1
  • The P-III IMpassion130 study results: mPFS (7.4mos. vs 4.8 mos.); OS (43%); no new safety signals
  • Tecentriq + Abraxane is a combination of mAb targeting PD-L1 protein & chemotherapeutic agent. Tecentriq is approved in EU, the US and other 85 countries for NSCLC & mUC

Click here to read full press release/ article | Ref: Roche | Image: Chemical Industry Digest

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post